The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma

BACKGROUND: Human epidermal growth factor receptor-2 (Her-2) is over expressed in approximately 25-30% of all primary breast tumors resulting in a distinctive breast cancer subtype associated with a poor prognosis and a decrease in overall survival. Trastuzumab (Herceptin®), an anti-Her-2 monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurrell, Tracey, Outhoff, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852844/
https://www.ncbi.nlm.nih.gov/pubmed/24119761
http://dx.doi.org/10.1186/1475-2867-13-97

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852844/
https://www.ncbi.nlm.nih.gov/pubmed/24119761
http://dx.doi.org/10.1186/1475-2867-13-97

Ejemplares similares